Histotripsy for Liver Tumors: Expanding Treatment Options Through Noninvasive Focused Ultrasound Technology

Histotripsy represents a significant advancement in the treatment of select liver tumors, offering a noninvasive, image-guided approach that mechanically destroys tumor tissue without surgery, thermal ablation or ionizing radiation. Moffitt Cancer Center is among the early adopters of this FDA-approved technology, providing access to the HistoSonics Edison® Histotripsy System for patients with primary and metastatic liver malignancies.

Histotripsy expands treatment options for select patients who may not be candidates for surgery or whose tumors are located near critical vascular or biliary structures, where other liver-directed therapies may be more challenging.

FDA-Approved Histotripsy Technology

The FDA-approved HistoSonics Edison® Histotripsy System uses high-intensity focused ultrasound to mechanically destroy targeted liver tumor tissue via acoustic cavitation. Unlike radiofrequency ablation, microwave ablation and other heat-based therapies, histotripsy does not rely on thermal energy to achieve tumor destruction.

During treatment, focused ultrasound waves generate microscopic bubbles within the tumor. As these bubbles rapidly expand and collapse, they generate mechanical forces that disrupt cellular structures and break down tumor tissue into acellular debris that the body can naturally clear. Because the mechanism is mechanical rather than thermal, histotripsy minimizes the risk of heat-related injury to surrounding tissues.

The procedure is performed under real-time imaging guidance, allowing physicians to continuously visualize treatment delivery and precisely target tumor tissue while minimizing effects on adjacent healthy structures.

How Histotripsy Differs From Other Liver-Directed Therapies

The primary distinction between histotripsy and many existing liver-directed treatments is its mechanism of action.

Traditional ablative therapies, including radiofrequency and microwave ablation, rely on thermal energy to induce tissue necrosis. While effective in many clinical scenarios, thermal techniques may be limited by proximity to major blood vessels due to the heat sink effect and may present challenges when treating tumors near sensitive biliary structures.

Radiation therapy, including stereotactic body radiation therapy (SBRT), utilizes ionizing radiation to damage tumor DNA and inhibit tumor growth. Although highly effective in many settings, radiation treatment typically requires multiple sessions and must balance tumor control with normal tissue exposure.

Histotripsy differs in that it:

• Uses focused ultrasound rather than heat or radiation
• Requires no incisions, needles or probes
• Avoids thermal injury to surrounding tissues
• Preserves critical vascular and biliary structures
• Provides real-time visualization during treatment
• Offers a completely noninvasive treatment approach

These characteristics may make histotripsy particularly attractive for patients with tumors located near major vessels or bile ducts where thermal ablation may be less desirable.

When to Consider Histotripsy

Histotripsy may be considered for select patients with primary liver cancers and metastatic liver disease. Clinical applications may include hepatocellular carcinoma, colorectal liver metastases and other liver lesions that are visible on imaging and accessible to ultrasound targeting.

Histotripsy may provide an additional local treatment option for select patients with unresectable liver tumors who are not candidates for surgery or other ablative approaches. It may also be valuable when lesion location, patient comorbidities or prior treatments limit other local treatment options.

Emerging Research and Future Potential

Interest in histotripsy extends beyond local tumor destruction. Early studies suggest that the mechanical disruption of tumor tissue may stimulate an antitumor immune response, a phenomenon referred to as immunomodulation. While additional clinical investigation is needed, this area of research has generated considerable interest regarding the future integration of histotripsy with immunotherapy and other systemic treatment approaches.

Research is also ongoing to evaluate potential applications of histotripsy in tumor types beyond the liver, further expanding interest in this evolving technology.

To refer a patient to Moffitt for evaluation and consideration of histotripsy, physicians can complete our online referral form or contact a physician liaison for assistance.